- Home
- NTRB vs RAND Comparison
NTRB vs RAND Comparison
Compare NTRB & RAND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NTRB
- RAND
- Stock Information
- Founded
- NTRB 2016
- RAND 1969
- Country
- NTRB United States
- RAND United States
- Employees
- NTRB N/A
- RAND N/A
- Industry
- NTRB Industrial Specialties
- RAND Finance: Consumer Services
- Sector
- NTRB Health Care
- RAND Finance
- Exchange
- NTRB Nasdaq
- RAND Nasdaq
- Market Cap
- NTRB 59.1M
- RAND 57.6M
- IPO Year
- NTRB N/A
- RAND N/A
- Fundamental
- Price
- NTRB $7.50
- RAND $15.48
- Analyst Decision
- NTRB Buy
- RAND
- Analyst Count
- NTRB 1
- RAND 0
- Target Price
- NTRB $13.00
- RAND N/A
- AVG Volume (30 Days)
- NTRB 82.0K
- RAND 6.1K
- Earning Date
- NTRB 05-30-2025
- RAND 08-05-2025
- Dividend Yield
- NTRB N/A
- RAND 7.47%
- EPS Growth
- NTRB N/A
- RAND 39.77
- EPS
- NTRB N/A
- RAND 3.12
- Revenue
- NTRB $2,398,437.00
- RAND $8,499,970.00
- Revenue This Year
- NTRB $560.75
- RAND N/A
- Revenue Next Year
- NTRB $588.39
- RAND N/A
- P/E Ratio
- NTRB N/A
- RAND $4.98
- Revenue Growth
- NTRB 18.92
- RAND 12.52
- 52 Week Low
- NTRB $3.72
- RAND $14.01
- 52 Week High
- NTRB $11.78
- RAND $31.89
- Technical
- Relative Strength Index (RSI)
- NTRB 59.79
- RAND 42.20
- Support Level
- NTRB $7.00
- RAND $15.15
- Resistance Level
- NTRB $7.90
- RAND $15.75
- Average True Range (ATR)
- NTRB 0.66
- RAND 0.52
- MACD
- NTRB -0.01
- RAND 0.14
- Stochastic Oscillator
- NTRB 37.45
- RAND 36.67
About NTRB Nutriband Inc.
Nutriband Inc is engaged in the development of a portfolio of transdermal pharmaceutical products. AVERSA technology is the company's product that incorporates aversive agents to prevent the Abuse, Diversion, Misuse, and Accidental exposure of drugs with abuse potential specifically Opioids. The majority of the revenue is generated from the sale of goods that include consumer transdermal and coated products.
About RAND Rand Capital Corporation
Rand Capital Corp is a closed-end, externally managed, non-diversified investment company. The company's investment objective is to generate current income and, when possible, complement its current income with capital appreciation by focusing its debt and related equity investments in privately-held, lower middle market companies with committed and experienced managements in a broad variety of industries. It predominantly invests in higher-yielding debt instruments.